Clinical Trials

As an academic medical center, Our Lady of the Lake is committed to the advancement of healthcare through clinical innovation, medical education and scientific research.  We participate in a wide range of clinical trials that are used to determine whether new drugs or treatments are both safe and effective.

Be sure to consult with your physician before participating in a clinical trial.

Clinical Trials by Specialty

AUDIOLOGY
BLOOD DISORDERS
CANCER
DIABETES
GASTROENTEROLOGY
GENETIC DISEASES
INFECTIOUS DISEASES
NEUROLOGICAL
SURGICAL

AUDIOLOGY

Title:  Safety And Efficacy For The Eustachian Tube Balloon Catheter

Purpose:  The purpose of this research study is to test the use of a device to treat Eustachian Tube Dysfunction (ETD).

Principal Investigator:  Dr. Moisés A. Arriaga

Contact:  For more information, contact Ryan Landry, BSN, CCRN at (225) 765-2104.

BLOOD DISORDERS

Title:  Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC)

Purpose:  The purpose of this research study is to learn if MST-188 can decrease the amount of time children with sickle cell disease are in painful vaso-occlusive crisis.

Principal Investigator:  Dr. Vandy Black

Contact:  For more information, contact Ryan Landry, BSN, CCRN at (225) 765-2104.

***

Title:  Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Purpose:  The purpose of this study is to evaluate the safety and effectiveness of new medication SelG1 in the treatment of patients with sickle cell disease who experience sickle cell-related pain crises.

Principal Investigator:  Dr. Vandy Black

Contact:  For more information, contact Christine LeBoeuf, MSN, RN, OCN at (225) 765-5956.

CANCER

Title:  An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Purpose:  The purpose of this study is to collect information on how patients who have metastic breast cancer are treated and how they respond to the various treatments.

Principal Investigator:  Dr. Patrick Stagg, II

Contact:  For more information, contact Christine LeBoeuf, MSN, RN, OCN at (225) 765-5956.

***

Title:  A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Purpose:  The purpose of this study is to compare the effects of ibrutinib when given in combination with rituximab, cyclohosphamide, doxorubicin, vincristine and prednisone (R-CHOP) versus RCHOP and placebo.

Principal Investigator:  Dr. Vince Calaldo

Contact:  For more information, contact Christine LeBoeuf, MSN, RN, OCN at (225) 765-5956.

***

Title:  Compare the Efficacy and Tolerability of Fulvestrant with Anastrozole as Hormonal Treatment for Postmenopausal Women with Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Purpose:  The purpose of this research is to find out more about the treatment of cancer of the breast or cancer that has spread to areas of the body that are distant to it.

Principal Investigator:  Dr. Vince Calaldo

Contact:  For more information, contact Christine LeBoeuf, MSN, RN, OCN at (225) 765-5956.

***

Title:  Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Purpose:  The purpose of this study is to better understand patterns related to diagnosis, treatment and outcomes for patients, and to better understand the effect different treatments have on a patient’s disease and their quality of life.

Principal Investigator:  Dr. Vince Calaldo

Contact:  For more information, contact Christine LeBoeuf, MSN, RN, OCN at (225) 765-5956.

***

*Coming Soon*

Title: A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination with Bevacizumab in Patients with Metastatic Renal Cell Carcinoma (RCC) versus the Standard of Care

Purpose: The purpose of this research study is to determine how well CRLX101 (study drug) in combination with Avastin works in treating  renal cell cancer that stops responding to treatment.

Principal Investigator:  Dr. Vince Calaldo

Contact:  For more information, contact Christine LeBoeuf, MSN, RN, OCN at (225) 765-5956.

DIABETES

Title:  Natural History of the Development of Type 1 Diabetes

Purpose:  The purpose of this study is to learn more about how Type 1 Diabetes occurs.

Principal Investigator:  Dr. James Garner

Contact:  For more information, contact Christine LeBoeuf, MSN, RN, OCN at (225) 765-5956.

GASTROENTEROLOGY

Title:  A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Subjects With Enteral Feeding Intolerance

Purpose:  The purpose of this study is to evaluate how safe a single dose of the study drug TD-8954 is for critically ill subjects with enteral feeding intolerance, how much of the study drug gets into the blood stream and how long the body takes to get rid of it.  In addition, this study compares TD-8954 to metoclopramide (Reglan), a medication that is already being prescribed to patients with enteral feeding intolerance.

Principal Investigator:  Dr. Cullent Hebert

Contact:  For more information, contact Ryan Landry, BSN, CCRN at (225) 765-2104

GENETIC DISEASES

Title:  A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease

Purpose:  The purpose of this study is to determine the percentage of patients with Pompe disease who are clinically stable or improved at week 52.

Principal Investigator:  Dr. Duane Superneau

Contact:  For more information, contact Jill Tomkins, BA, CCRP at (225) 765-7979.

INFECTIOUS DISEASES

*Coming Soon*

Title: Ceftolozane/Tazobactamcxa-Peds-13-08a Phase 1, Non Comparative, Open-Labelstudy To Characterize The Pharmacokinetics Of A Single Intravenousdose Of Ceftolozane/Tazobactam In Pediatric Patients Receiving Standard Of Care Antibiotic Therapy For Proven Or Suspected Gram-Negative Infection Or For Peri-Operative Prophylaxis

Purpose: To evaluate the pharmacokinetics (PK) of a single dose of intravenous ceftolozane/tazobactam in pediatric patients from birth to <18 years receiving standard of care antibiotic therapy for proven or suspected Gram-negative infection, including patients receiving peri-operative prophylactic antibiotics.

Principal Investigator:  Dr. Michael Bolton

Contact:  For more information , contact Dr. Susan Steele-Moses (225) 765-3344

NEUROLOGICAL

Title:  A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients with Traumatic Brain Injury (Intrepid2566)

Purpose:  The purpose of this study is to assess the safety of a new investigational drug, NNZ-2566, in human subjects with traumatic brain injury.

Principal Investigator:  Dr. Tomas Jacome

Contact:  For more information, contact Ryan Landry, BSN, CCRN at (225) 765-2104.

SURGICAL

Title:  Freedom Inguinal Hernia Repair

Purpose:  The purpose of this study is to determine how the Insightra Freedom Hernia Device impacts quality of life for patients.

Principal Investigator:  Dr. Karl LeBlanc

Contact:  For more information, contact Ryan Landry, BSN, CCRN at (225) 765-2104.

***

*Coming Soon*

Title:  Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated Wtih Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures

Purpose:  The purpose of this study is to reverse the anticoagulent effects of Dabigatran in patients who have overt bleeding, or who require emergency surgery or invasive procedures.

Principal Investigator:  Dr. Michael Fahr

Contact:  For more information, contact Ryan Landry, BSN, CCRN at (225) 765-2104.